Neurology
Epilepsy Innovation Just Hit a Safety Wall
FDA has paused new enrolment in Biohaven’s opakalim programme over insufficient information on a metabolite identified in rodent testing. The programme has not failed, but promising clinical data do not cancel basic safety obligations.
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Rare Epilepsy Moves Toward Treating the Cause
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases